Premium
Changes in VEGF and HIF 1α gene expression levels as potential diagnostic/prognostic markers in liquid biopsies on breast cancer patients
Author(s) -
Peiró Carlos Henrique Foncesca,
Encinas Jéssica Freitas Araújo,
Aquino Glauco Sérgio Avelino,
Veiga Glaucia Luciano,
Perez Matheus Moreira,
Fonseca Fernando Luiz Affonso,
Alves Beatriz Costa Aguiar
Publication year - 2019
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2019.33.1_supplement.lb310
Subject(s) - breast cancer , medicine , chemotherapy , trizol , cancer , gene expression , gastroenterology , pathology , gene , oncology , rna extraction , biology , biochemistry
Aim This study aimed to evaluate the potential diagnostic and/or prognostic value of VEGF and HIF 1α gene expressions in peripheral blood of patients with breast cancer under chemotherapy treatment. Methods Peripheral blood samples and tumor biopsies were collected from 125 patients with breast cancer and from 25 healthy women (control). Blood samples were collected at diagnosis and after 3 and 6 months of the beginning of chemotherapy. Total RNA isolation was performed using TRIZol reagent. RNA was then converted to cDNA and the gene expression analysis was made by RT‐qPCR. Results were expressed as mean ± standard deviation and analysed by GraphPad Prism ® 6.0 using Mann‐Withney, Friedman and Spearman tests, with a significancy level established in 5% (value of p< 0,05). Results Gene expression analysis showed an increase of HIF 1α gene expression in patients at diagnosis when compared to that of healthy women (Patients: 0.3362 ± 0.7729, n=34 vs Donors: 0.00212 ± 0.001509, n=25, *p<0.0001). Analysis showed that in patients HIF 1α and VEGF expression is higher in peripheral blood than tumor samples (blood: 0.1927 ± 0.4754, n=108 vs Tumor: 0.09498 ± 0.2141, n=91, *p<0.0001 for HIF 1α and blood: 0.001436 ± 0.002469, n=117, Tumor: 0.002364 ± 0.007736, n=91 and *p=0.0041 for VEGF ). HIF 1α also showed a differential expression along treatment (at diagnosis: 0.1432 ± 0.2161, n=102; 3 months after chemotherapy: 0.2010 ± 0.3456, n=102 and 6 months after chemotherapy: 0.1657 ± 0.2150, n=102, *p=0.0021). This differential expression along treatment was also observed for VEGF expression (at diagnosis: 0.001314 ± 0.001780, n=112; 3 months after chemotherapy: 0.001891 ± 0.002446, n=112 and 6 months after chemotherapy: 0.001674 ± 0.002260, n=112, *p<0.0001). It was found a correlation between the gene expression levels of HIF 1α and VEGF in peripheral blood (r=05881, *p<0.0001) as well as in the tumor samples (r=0.2804, *p=0.0123). Conclusions Data suggest that HIF 1α could be a diagnosis marker since there's a significant increase in its expression in blood samples from breast cancer patients when compared to healthy women. It's also observed that there's a positive correlation between VEGF and HIF 1α gene expression in peripheral blood samples. Support or Funding Information Financing: CNPq (process number: 133505/2018‐9) and FAPESP (Process number: 2017/03558‐3). Associated author: Carlos Henrique Foncesca Peiró Association: ASBMB (Number: 64413). This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .